Will I Regain Weight After Stopping GLP-1? What Malaysian Patients Need to Know

One of the most common questions from patients considering GLP-1 treatment is: 'If I stop the injection, will all the weight come back?' It is a fair and important question. Clinical data shows that weight regain after stopping GLP-1 medication is real, but it is not inevitable, and it is manageable with the right approach. Understanding why this happens, and what to do about it, is essential before starting treatment.

Why Does Weight Return After Stopping GLP-1?

Obesity is a chronic biological condition driven by hormonal, metabolic, and neurological factors, not simply a matter of willpower or temporary dietary choices. GLP-1 medications work by correcting dysregulation in appetite-signalling hormones, particularly GLP-1 itself (which is deficient in people with obesity) and ghrelin (the hunger hormone). When the medication is stopped, these hormonal signals return to their pre-treatment patterns.

The clinical data from the STEP 1 extension study (STEP 1 SUSTAIN) is instructive: patients who stopped semaglutide after 68 weeks of treatment regained approximately two-thirds of their lost weight within one year of cessation. This is not a failure of the medication. It reflects the chronic nature of obesity as a disease that requires ongoing management.

This pattern is directly comparable to other chronic conditions. When a patient stops blood pressure medication, blood pressure typically rises again. When a patient stops cholesterol-lowering medication, cholesterol levels return. The same principle applies to GLP-1 treatment for obesity, which is why many clinicians view GLP-1 as a long-term or even indefinite treatment rather than a short course.

Is Weight Regain Guaranteed?

Weight regain after stopping GLP-1 is common but not universal or total. The clinical picture is more nuanced than it might initially appear. Patients who have made meaningful and lasting changes to their dietary habits and physical activity during the treatment period tend to maintain significantly more of their weight loss.

Some patients maintain 50-70% of their total weight loss for two or more years after stopping medication, particularly when they have addressed underlying contributing conditions such as PCOS, type 2 diabetes, or obstructive sleep apnoea during treatment. The treatment window creates an opportunity to build sustainable behaviours that persist beyond the active medication phase.

The key insight is that GLP-1 treatment is most effective when patients use the reduced-appetite window as a foundation for building sustainable lifestyle habits: improved dietary patterns, regular physical activity, better sleep rather than relying on the medication as a standalone intervention. The medication creates favourable conditions for change; sustained change requires intentional effort.

Who Is at Higher Risk of Regaining Weight?

Patients who are at higher risk of significant weight regain after stopping GLP-1 include those who relied primarily on the medication without making concurrent lifestyle changes, those with ongoing hormonal or metabolic conditions that drive weight gain (such as untreated PCOS, poorly controlled T2D, or untreated sleep apnoea), and those who had a very high starting BMI.

Patients who have not established a regular exercise routine, particularly resistance training, which preserves metabolically active muscle mass, are also at higher risk of regain. Understanding your personal risk profile for regain is an important part of planning your GLP-1 treatment journey with your doctor.

5 Strategies to Minimise Weight Regain After GLP-1

The Concept of GLP-1 as Chronic Disease Management

The medical community increasingly recognises obesity as a chronic disease requiring ongoing management, analogous to hypertension, type 2 diabetes, or hypercholesterolaemia. Treating these conditions temporarily and then stopping medication when numbers improve does not address the underlying chronic condition; it simply pauses the treatment.

For many patients, the most clinically appropriate approach is long-term GLP-1 treatment, potentially indefinitely rather than a fixed treatment course. This framing removes the pressure of 'finishing' treatment and instead frames GLP-1 as ongoing metabolic support. Your Seimbang doctor can help you understand whether long-term treatment is appropriate for your situation.

Planning Your GLP-1 Journey with Seimbang

At Seimbang, we help patients plan the full arc of their GLP-1 treatment, not just the active medication phase. This includes discussing realistic expectations for the duration of treatment, strategies for building sustainable habits during treatment, and thoughtful planning for the eventual transition off medication when appropriate.

If you are considering stopping your GLP-1 treatment, we strongly recommend scheduling a check-in with your Seimbang doctor first. We can review your progress, assess your risk of regain, help design a supervised tapering plan if stopping is appropriate, and discuss whether maintenance dosing might be a better option for your long-term health.

Frequently Asked Questions